Evidence map›Paper›PMID 38806800›Full record

ArticleOrthopadie (Heidelberg, Germany)2024

[Update of the S3-guideline on diagnostics, prophylaxis and treatment of osteoporosis].

Michael Drey, Sven Otto, Friederike Thomasius, Ralf Schmidmaier

Abstract read
PubMed Publisher
In one paragraph

Article in Orthopadie (Heidelberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. [Metabolic bone disorders: what the internist must not overlook].Innere Medizin (Heidelberg, Germany) · 2026
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael DreyMedizinische Klinik IV, Schwerpunkt Geriatrie, LMU Klinikum München, Ziemssenstraße 5, 80336, München, Deutschland. Michael.Drey@med.uni-muenchen.de.
Sven OttoKlinik und Poliklinik für Mund-Kiefer-Gesichtschirurgie, LMU Klinikum München, München, Deutschland.
Friederike ThomasiusFrankfurter Hormon & Osteoporosezentrum, Frankfurt, Deutschland.
Ralf SchmidmaierMedizinische Klinik IV, Schwerpunkt Geriatrie, LMU Klinikum München, Ziemssenstraße 5, 80336, München, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the aid of a new fracture risk model, the great treatment gap for osteoporosis should be closed. All patients older than 70 years should undergo a diagnostic procedure for osteoporosis. An additional risk threshold (≥ 10% per 3 years for femoral and vertebral fractures) should enable patients with a high risk of fracture to be treated with osteoanabolic agents. The use of osteoanabolic agents makes it necessary to administer antiresorptive drugs afterwards. Due to the low event rate of osteonecrosis of the jaw, the initiation of a specific osteoporosis treatment should not be delayed by prophylactic dental treatment. The adherence to the drug treatment should be improved by an individualized approach on the basis of a cooperation between patients, caregivers, and physicians. A regular assessment of falls, including the timed up and go test should be carried out in patients older than 70 years.

Indexed as

Bone Density Conservation AgentsOsteoporosisOsteoporotic FracturesPractice Guidelines as TopicAgedFemaleHumansMaleBone Density Conservation AgentsFractureFracture riskFracture risk modelHigh risk patientOsteoanabolic agent

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.